Skip to main content

Advertisement

SpringerLink
Log in

Candida haemulonii sensu lato: Update of the Determination of Susceptibility Profile in Argentina and Literature Review

  • Clinical Mycology Lab Issues (S Córdoba, Section Editor)
  • Published:
Current Fungal Infection Reports Aims and scope Submit manuscript

Abstract

Purpose of review

This review summarizes the information available of Candida haemulonii sensu lato, and updates the in vitro susceptibility profile of the isolates of these species from Argentina. C. haemulonii sensu lato causes fungemia in low frequency in adults and children; however, the knowledge about this emerging yeast is relevant since it is considered as a multi-resistant pathogen.

Recent findings

The discovery of new antifungal molecules, the determination of epidemiological cutoff value and clinical breakpoints for some yeasts of clinical impact, and the update of techniques to determine the in vitro susceptibility profile to yeast have generated some available information, although, for C. haemulonii sensu lato, this information is not always useful for clinical application.

Summary

We determined the susceptibility profile of C. haemulonii sensu lato strains isolated in Argentina, as a first step to establish the epidemiological cutoff values in our region. We also review the current situation in other countries.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Cendejas-Bueno E, Kolecka A, Alastruey-Izquierdo A, Theelen B, Groenewald M, Kostrzewa M, et al. Reclassification of the Candida haemulonii complex as Candida haemulonii (C. haemulonii group I), C. duobushaemulonii sp. nov. (C. haemulonii group II), and C. haemulonii var. vulnera var. nov.: three multiresistant human pathogenic yeasts. J Clin Microbiol. 2012;50:3641–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Almeida JN Jr, Motta AL, Rossi F, Abdala E, Pierrotti LC, et al. First report of a clinical isolate of Candida haemulonii in Brazil. Clinics. 2012;67:1229–31.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Khan ZU, Al-Sweih NA, Ahmad S, Al-Kazemi N, Khan S, Joseph L, et al. Outbreak of fungemia among neonates caused by Candida haemulonii resistant to amphotericin B, itraconazole and fluconazole. Clin Microbiol. 2007;45:2025–7.

    Article  CAS  Google Scholar 

  4. Muro MD, Motta F de A, Burger M, Melo AS, Dalla-Costa LM. Echinocandin resistance in two Candida haemulonii isolates from pediatric patients. J Clin Microbiol. 2012;50:3783–5.

  5. Silva CM, Carvalho-Parahym AM, Macêdo DP, Lima-Neto RG, Francisco EC, Melo AS, et al. Neonatal candidemia caused by Candida haemulonii: case report and review of literature. Mycopathologia. 2015;180:69–73.

    Article  PubMed  Google Scholar 

  6. Kim MN, Shin JH, Sung H, Lee K, Kim EC, Ryoo N, et al. Candida haemulonii and closely related species at 5 university hospitals in Korea: identification, antifungal susceptibility, and clinical features. Clin Infec Diseases. 2009;48:57–61.

    Article  Google Scholar 

  7. Crouzet J, Sotto A, Picard E, Lachaud L, Bourgeois N. A case of Candida haemulonii osteitis: clinical features, biochemical characteristics, and antifungal resistance profile. Clin Microbiol Infect. 2011;17:1068–70.

    Article  CAS  PubMed  Google Scholar 

  8. Yuvaraj A, Rohit A, Koshy PJ, Nagarajan P, Nair S, Abraham G. Rare occurrence of fatal Candida haemulonii peritonitis in a diabetic CAPD patient. Ren Fail. 2014;36:1466–7.

    Article  PubMed  Google Scholar 

  9. Fang SY, Wei KC, Chen WC, Lee SJ, Yang KC, Wu CS, et al. Primary deep cutaneous candidiasis caused by Candida duobushaemulonii in a 68-year-old man: the first case report and literature review. Mycoses. 2016;Sep:1–4.

  10. • Kumar A, Prakash A, Singh A, Kumar H, Hagen F, Meis JF, et al. Candida haemulonii species complex: an emerging species in India and its genetic diversity assessed with multilocus sequence and amplified fragment-length polymorphism analyses. Emerg Microbes Infect. 2016;25-5:e49. This work contains an important number of strains, and the determination of the MICs was performed following a reference methodology.

  11. Chowdhary A, Anil Kumar V, Sharma C, Prakash A, Agarwal K, Babu R, et al. Multidrug-resistant endemic clonal strain of Candida auris in India. Eur J Clin Microbiol Infect Dis. 2014;33:919–26.

    Article  CAS  PubMed  Google Scholar 

  12. • Kathuria S, Singh PK, Sharma C, Prakash A, Masih A, Kumar A, et al. Multidrug-resistant Candida auris misidentified as Candida haemulonii: characterization by matrix-assisted laser desorption ionization-time of flight mass spectrometry and DNA sequencing and its antifungal susceptibility profile variability by Vitek 2, CLSI broth microdilution, and Etest method. J Clin Microbiol. 2015;53:1823–30. This work contains an important number of strains, and the determination of the MICs was performed following a standard reference method.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Hou X, Xiao M, Chen SC, Wang H, Cheng JW, Chen XX, et al. Identification and antifungal susceptibility profiles of Candida haemulonii species complex clinical isolates from a multicenter study in China. J Clin Microbiol. 2016;54:2676–80.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Grenfell RC, da Silva Junior AR, Del Negro GM, Munhoz RB, Gimenes VM, Assis DM, et al. Identification of Candida haemulonii complex species: use of ClinProTools™ to overcome limitations of the Bruker Biotyper™, VITEK MS™ IVD, and VITEK MS™ RUO databases. Front Microbiol. 2016;7:940.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Sarma S, Upadhyay S. Current perspective on emergence, diagnosis and drug resistance in Candida auris. Infect Drug Resist. 2017;10:155–65.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Kordalewska M, Zhao Y, Lockhart SR, Chowdhary A, Berrio I, Perlin DS. Rapid and accurate molecular identification of the emerging multidrug-resistant pathogen Candida auris. J Clin Microbiol. 2017;55:2445–52.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Oh BJ, Shin JH, Kim MN, Sung H, Lee K, et al. Biofilm formation and genotyping of Candida haemulonii, Candida pseudohaemulonii, and a proposed new species (Candida auris) isolates from Korea. Med Mycol. 2011;49:98–102.

    Article  PubMed  Google Scholar 

  18. Rodero L, Cuenca-Estrella M, Córdoba S, Cahn P, Davel G, Kaufman S, et al. Transient fungemia caused by an amphotericin B-resistant isolate of Candida haemulonii. J Clin Microbiol. 2002;40:2266–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Cordoba S, Vivot W, Bosco-Borgeat ME, Taverna C, Szusz W, Murisengo O, et al. Species distribution and susceptibility profile of yeasts isolated from blood cultures: results of a multicenter active laboratory-based surveillance study in Argentina. Rev Argent Microbiol. 2011;43:176–85.

    CAS  PubMed  Google Scholar 

  20. Nucci M, Queiroz-Telles F, Alvarado-Matute T, Tiraboschi IN, Cortes J, Zurita J, et al. Epidemiology of candidemia in Latin America: a laboratory-based survey. PLoS One. 2013;8:e59373.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. • Santolaya ME, Alvarado T, Queiroz-Telles F, Colombo AL, Zurita J, Tiraboschi IN, et al. Latin American Invasive Mycosis Network. Active surveillance of candidemia in children from Latin America: a key requirement for improving disease outcome. Pediatr Infect Dis J. 2014;33:e40–4. This study was conducted in Latin American countries in children provides information about the epidemiology of yeast infections in region.

    Article  PubMed  Google Scholar 

  22. Ben-Ami R, Berman J, Novikov A, Bash E, Shachor-Meyouhas Y, Zakin S, et al. Multidrug-resistant Candida haemulonii and C. auris, Tel Aviv, Israel. Emerg Infect Dis. 2017;23:195–203.

    Article  PubMed Central  Google Scholar 

  23. Guinea J, Zaragoza O, Escribano P, Martin-Mazuelos E, Peman J, Sanchez-Reus F, et al. Molecular identification and antifungal susceptibility of yeast isolates causing fungemia collected in a population-based study in Spain in 2010 and 2011. Antimicrob Agents Chemother. 2014;58:1529–37.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Faria-Ramos I, Neves-Maia J, Ricardo E, Santos-Antunes J, Silva AT, Costa-de-Oliveira S, et al. Erratum to: species distribution and in vitro antifungal susceptibility profiles of yeast isolates from invasive infections during a Portuguese multicenter survey. Eur J Clin Microbiol Infect Dis. 2015;34:2137.

    Article  CAS  PubMed  Google Scholar 

  25. Minea B, Nastasa V, Moraru RF, Kolecka A, Flonta MM, Marincu I, et al. Species distribution and susceptibility profile to fluconazole, voriconazole and MXP-4509 of 551 clinical yeast isolates from a Romanian multi-centre study. Eur J Clin Microbiol Infect Dis. 2015;34:367–83.

    Article  CAS  PubMed  Google Scholar 

  26. Meletiadis J, Geertsen E, Curfs-Breuker I, Meis JF, Mouton JW. Intra- and interlaboratory agreement in assessing the in vitro activity of micafungin against common and rare Candida species with the EUCAST, CLSI, and Etest methods. Antimicrob Agents Chemother. 2016;60:6173–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Nucci M, Thompson-Moya L, Guzman-Blanco M, Tiraboschi IN, Cortes JA, Echevarría J, et al. Grupo Proyecto Épico. Recommendations for the management of candidemia in adults in Latin America. Grupo Proyecto Épico. Rev Iberoam Micol. 2013;30:179–88.

    Google Scholar 

  28. Santolaya ME, de Queiroz Telles F, Alvarado Matute T, Colombo AL, Zurita J, Tiraboschi IN, et al. Recommendations for the management of candidemia in children in Latin America. Rev Iberoam Micol. 2013;30:171–8.

  29. •• Pappas PG, Kauffman CA, Andes D, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical practice guidelines for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62:1–50. Last update of therapeutic guidelines of candidiasis.

  30. •• European Committee for Antimicrobial Susceptibility Testing (EUCAST) Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts, Eucast Definitive Document E.Def 7.3 January 2017. Methodology applied in this work.

  31. • European Committee on Antimicrobial Susceptibility Testing (EUCAST). Antifungal Agents. Breakpoint tables for interpretation of MICs Version 8.1 valid from 2017–03-01 www.eucast.org 2017;1–5. Current Clinical Breakpoint used for the interpretation of MICs.

  32. Kurtzman CP, Fell JW, Boekhout T, editors. The yeast: a taxonomic study. 5th ed. Amsterdam: Elsevier; 2011.

    Google Scholar 

  33. Taverna CG, Bosco-Borgeat ME, Murisengo OA, Davel G, Boité MC, Cupolillo E, et al. Comparative analyses of classical phenotypic method and ribosomal RNA gene sequencing for identification of medically relevant Candida species. Mem Inst Oswaldo Cruz. 2013;108:178–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Schoch CL, Seifert KA, Huhndorf S, Robert V, Spouge JL, Levesque CA, et al. and Fungal Barcoding Consortium Nuclear ribosomal internal transcribed spacer (ITS) region as a universal DNA barcode marker for Fungi. Proc Natl Acad Sci U S A. 2012;109:6241–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Ciardo DE, Schär G, Böttger EC, Altwegg M, Bosshard PP. Internal transcribed spacer sequencing versus biochemical profiling for identification of medically important yeasts. J Clin Microbiol. 2006;44:77–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Nilsson RH, Kristiansson E, Ryberg M, Hallenberg N, Larsson KH. Intraspecific ITS variability in the kingdom Fungi as expressed in the international sequence databases and its implications for molecular species identification. Evol Bioinformatics Online. 2008;4:193–201.

    Google Scholar 

  37. Kurtzman CP, Piskur J 2005. Taxonomy and phylogenetic diversity among the yeasts. Top Curr Genet 15.

  38. Orasch C, Marchetti O, Garbino J, Schrenzel J, Zimmerli S, Mühlethaler K, et al. Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards institute clinical breakpoints: a 6-year prospective candidaemia survey from the fungal infection network of Switzerland. Clin Microbiol Infect. 2014;20:698–705.

    Article  CAS  PubMed  Google Scholar 

  39. Ruan SY, Kuo YW, Huang CT, Hsiue HC, Hsueh PR. Infections due to Candida haemulonii: species identification, antifungal susceptibility and outcomes. Antimicrob Agents. 2010;35:85–8.

    Article  CAS  Google Scholar 

  40. Shin JH, Kim MN, Jang SJ, MY J, Kim SH, Shin MG, et al. Detection of amphotericin B resistance in Candida haemulonii and closely related species by use of the Etest, Vitek-2 yeast susceptibility system, and CLSI and EUCAST broth microdilution methods. J Clin Microbiol. 2012;50:1852–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Garcia-Effron G, Katiyar SK, Park S, Edlind TD, Perlin DS. A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob Agents Chemother. 2008;52:2305–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. • Ramos LS, Figueiredo-Carvalho MH, Barbedo LS, Ziccardi M, Chaves AL, Zancopé-Oliveira RM, et al. Candida haemulonii complex: species identification and antifungal susceptibility profiles of clinical isolates from Brazil. J Antimicrob Chemother. 2015;70(1):111–5. This work contains a significant number of strain; the determination of MICs was developed following a reference methodology and provides the profile of antifungal susceptibility of circulating strains in Latin America.

    Article  CAS  PubMed  Google Scholar 

  43. • de Almeida JN Jr, Assy JG, Levin AS, Del Negro GM, Giudice MC, Tringoni MP, et al. Candida haemulonii Complex Species, Brazil, January 2010–March 2015. Emerg Infect Dis. 2016;22:561–3. This work contains a significant number of strains; the determination of MICs was developed following a reference methodology and provides the profile of susceptibility of circulating strains in Latin America.

    Article  PubMed  Google Scholar 

  44. Sugita T, Takashima M, Poonwan N, Mekha N. Candida pseudohaemulonii sp. nov., an amphotericin B-and azole-resistant yeast species, isolated from the blood of a patient from Thailand. MicrobiolImmunol. 2006;50:469–73.

    CAS  Google Scholar 

  45. Arendrup MC, Prakash A, Meletiadis J, Sharma C, Chowdhary A. Comparison of EUCAST and CLSI reference microdilution MICs of eight antifungal compounds for Candida auris and associated tentative epidemiological cutoff values. Antimicrob Agents Chemother. 2017;24:61.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departamento de Micología, Instituto Nacional de Enfermedades Infecciosas “Dr. Carlos G. Malbrán”, Avenida Vélez Sarsfield 563, Buenos Aires, Argentina

    Guillermina Isla, Constanza G. Taverna, Wanda Szusz, Walter Vivot & Graciela Davel

  2. Laboratorio de Micología y Diagnóstico Molecular. Cátedra de Parasitología y Micología. Facultad de Bioquímica y Ciencias Biológicas, Universidad Nacional del Litoral, Santa Fe, Argentina

    Guillermo García-Effron

  3. Consejo Nacional de Investigaciones Científicas y Tecnológicas (CONICET), Santa Fe, Argentina

    Guillermo García-Effron

Authors
  1. Guillermina Isla
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Constanza G. Taverna
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wanda Szusz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Walter Vivot
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Guillermo García-Effron
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Graciela Davel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Guillermina Isla.

Ethics declarations

Conflict of Interest

The authors declare that they have no competing interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Clinical Mycology Lab Issues

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Isla, G., Taverna, C.G., Szusz, W. et al. Candida haemulonii sensu lato: Update of the Determination of Susceptibility Profile in Argentina and Literature Review. Curr Fungal Infect Rep 11, 203–208 (2017). https://doi.org/10.1007/s12281-017-0300-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12281-017-0300-y

Keywords

Search

Navigation